What is Expedition Therapeutics?
Expedition Therapeutics is a specialized biotechnology firm dedicated to the development of disease-modifying treatments for chronic obstructive pulmonary disease. The company focuses on the clinically validated pathway of neutrophilic inflammation, which is intrinsically linked to tissue damage and airway remodeling. By developing novel, once-daily oral inhibitors, Expedition Therapeutics aims to disrupt the standard of care for COPD, moving beyond symptomatic relief toward addressing the underlying biological drivers of the disease. Its market position is bolstered by a strong syndicate of life sciences investors who provide both financial resources and deep clinical expertise.
How much funding has Expedition Therapeutics raised?
Expedition Therapeutics has raised a total of $280M across 2 funding rounds:
Series A
$165M
Series B
$115M
Series A (2025): $165M with participation from Logos Capital Partners Sa rl, Forbion, Sofinnova Partners, Novo Holdings, and Sanofi Ventures
Series B (2026): $115M led by Adage Capital Management, BVF Partners, General Atlantic, Logos Capital, Sofinnova, Sanofi Ventures, Novo Holdings, Venrock, Forbion, Balyasny Asset Management, RA Capital Management, and Vivo Capital
Key Investors in Expedition Therapeutics
Forbion
A global life sciences venture capital firm that sources and guides biotech companies from early-stage development through to clinical maturity.
Novo Holdings
A Danish private limited liability company wholly owned by the Novo Nordisk Foundation, focused on long-term investments in life sciences.
Sanofi Ventures
The corporate venture capital arm of Sanofi, investing in early-stage biotech and digital health companies with transformative potential.
What's next for Expedition Therapeutics?
With the successful closure of this latest financing round, Expedition Therapeutics is well-positioned to transition its lead candidate through critical clinical milestones. The strategic focus will remain on the rigorous evaluation of its DPP1 inhibitor, ensuring that the clinical data supports the company's goal of providing a transformative therapeutic option for the COPD patient population. As the firm scales its operations, it will likely prioritize regulatory engagement and the expansion of its internal research capabilities to further validate its approach to inflammatory disease management. The continued support from top-tier venture partners suggests a clear path toward potential commercialization and long-term value creation in the respiratory therapeutics sector.
See full Expedition Therapeutics company page
